Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Get Free Report) was the recipient of a large decline in short interest in the month of June. As of June 15th, there was short interest totalling 21,570,000 shares, a decline of 14.2% from the May 31st total of 25,140,000 shares. Based on an average daily volume of 2,810,000 shares, the short-interest ratio is presently 7.7 days.
Lexicon Pharmaceuticals Trading Down 4.5 %
NASDAQ LXRX traded down $0.07 during trading hours on Tuesday, reaching $1.60. The company had a trading volume of 1,764,918 shares, compared to its average volume of 3,724,318. The stock has a market capitalization of $393.98 million, a P/E ratio of -1.93 and a beta of 1.35. Lexicon Pharmaceuticals has a 1-year low of $0.92 and a 1-year high of $3.73. The company has a current ratio of 15.58, a quick ratio of 15.56 and a debt-to-equity ratio of 0.35. The stock has a 50-day moving average of $1.74 and a 200 day moving average of $1.92.
Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) last issued its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.02). The firm had revenue of $1.13 million during the quarter, compared to analyst estimates of $1.17 million. Lexicon Pharmaceuticals had a negative net margin of 8,311.12% and a negative return on equity of 108.54%. As a group, research analysts anticipate that Lexicon Pharmaceuticals will post -0.7 earnings per share for the current fiscal year.
Analyst Ratings Changes
Get Our Latest Analysis on Lexicon Pharmaceuticals
Hedge Funds Weigh In On Lexicon Pharmaceuticals
A number of hedge funds have recently modified their holdings of LXRX. Virtu Financial LLC acquired a new position in shares of Lexicon Pharmaceuticals during the 1st quarter worth $105,000. Boulder Hill Capital Management LP purchased a new stake in shares of Lexicon Pharmaceuticals during the 1st quarter worth about $615,000. Vanguard Group Inc. grew its holdings in shares of Lexicon Pharmaceuticals by 7.0% during the 1st quarter. Vanguard Group Inc. now owns 6,401,225 shares of the biopharmaceutical company’s stock worth $15,363,000 after purchasing an additional 420,854 shares during the period. BNP Paribas Financial Markets grew its holdings in shares of Lexicon Pharmaceuticals by 82.6% during the 1st quarter. BNP Paribas Financial Markets now owns 59,378 shares of the biopharmaceutical company’s stock worth $143,000 after purchasing an additional 26,859 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Lexicon Pharmaceuticals by 65.7% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 46,930 shares of the biopharmaceutical company’s stock worth $113,000 after purchasing an additional 18,601 shares during the period. 74.70% of the stock is currently owned by hedge funds and other institutional investors.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.
Featured Stories
- Five stocks we like better than Lexicon Pharmaceuticals
- What is a Bond Market Holiday? How to Invest and Trade
- RXO Shares Surge Following New Acquisition Deal
- What Are Dividends? Buy the Best Dividend Stocks
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- How Can Investors Benefit From After-Hours Trading
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.